NO20002425D0 - FremgangsmÕte for diagnose av, eller forutsigelse av mottagelighet for en T-cellemedient sykdom hos et individ - Google Patents

FremgangsmÕte for diagnose av, eller forutsigelse av mottagelighet for en T-cellemedient sykdom hos et individ

Info

Publication number
NO20002425D0
NO20002425D0 NO20002425A NO20002425A NO20002425D0 NO 20002425 D0 NO20002425 D0 NO 20002425D0 NO 20002425 A NO20002425 A NO 20002425A NO 20002425 A NO20002425 A NO 20002425A NO 20002425 D0 NO20002425 D0 NO 20002425D0
Authority
NO
Norway
Prior art keywords
diagnosing
procedure
individual
predicting susceptibility
median disease
Prior art date
Application number
NO20002425A
Other languages
English (en)
Other versions
NO20002425L (no
Inventor
Mark D Howell
Steven W Brostoff
Dennis J Carlo
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27406453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20002425(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20002425L publication Critical patent/NO20002425L/no
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of NO20002425D0 publication Critical patent/NO20002425D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20002425A 1989-03-21 2000-05-10 FremgangsmÕte for diagnose av, eller forutsigelse av mottagelighet for en T-cellemedient sykdom hos et individ NO20002425D0 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32631489A 1989-03-21 1989-03-21
US38208689A 1989-07-18 1989-07-18
US38208589A 1989-07-18 1989-07-18
PCT/US1990/001516 WO1990011294A1 (en) 1989-03-21 1990-03-21 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Publications (2)

Publication Number Publication Date
NO20002425L NO20002425L (no) 1991-09-20
NO20002425D0 true NO20002425D0 (no) 2000-05-10

Family

ID=27406453

Family Applications (2)

Application Number Title Priority Date Filing Date
NO913722A NO309164B1 (no) 1989-03-21 1991-09-20 Fremgangsmåte for fremstilling av vaksine
NO20002425A NO20002425D0 (no) 1989-03-21 2000-05-10 FremgangsmÕte for diagnose av, eller forutsigelse av mottagelighet for en T-cellemedient sykdom hos et individ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO913722A NO309164B1 (no) 1989-03-21 1991-09-20 Fremgangsmåte for fremstilling av vaksine

Country Status (14)

Country Link
EP (1) EP0463101B2 (no)
JP (1) JP3472297B2 (no)
KR (1) KR920700674A (no)
AU (5) AU6892994A (no)
BG (1) BG61164B1 (no)
CA (1) CA2046909A1 (no)
DE (1) DE69006018T3 (no)
DK (1) DK0463101T3 (no)
ES (1) ES2062519T5 (no)
FI (1) FI914432A7 (no)
NO (2) NO309164B1 (no)
RO (1) RO110397B1 (no)
RU (1) RU2138512C1 (no)
WO (1) WO1990011294A1 (no)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
JPH06507384A (ja) * 1991-01-22 1994-08-25 ザ　イミューン　レスポンス　コーポレイション 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
DE69230612T2 (de) * 1991-05-31 2000-06-21 Connetics Corp., Palo Alto T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
JPH07504399A (ja) * 1991-08-28 1995-05-18 ザ・ウィスター・インスティチュート Ｔ細胞リセプターに基づいた慢性間接リウマチの治療法
JPH06511241A (ja) * 1991-09-23 1994-12-15 ジェネンテク，インコーポレイテッド 自己免疫疾患の診断および治療
CA2126686A1 (en) * 1991-12-24 1993-07-08 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
AU4529793A (en) * 1992-06-08 1994-01-04 Colorado State University Research Foundation Endogenous ligands for cdr4 of t-cell receptor beta -chains and genes encoding the same
JPH09500261A (ja) * 1993-05-14 1997-01-14 ドクトル エル．ウィレムス−インスティテュート ヒトｔ細胞モノクローン、その産生方法及び感染症、自己免疫疾患、ｔ細胞媒介アレルギー及びガンの診断上のその使用
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6034064A (en) * 1995-04-07 2000-03-07 Hoechst Pharmaceuticals & Chemicals K.K. Peptides and therapeutic agent for autoimmune diseases containing the same
RU2209633C2 (ru) * 1997-09-19 2003-08-10 Юниверсити Оф Саузерн Калифорниа Т-клеточная вакцина для лечения рассеянного склероза
WO2001097858A2 (en) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
PL373835A1 (en) 2001-01-31 2005-09-19 Biogen Idec Inc. Use of cd23 antagonists for the treatment of neoplastic disorders
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
BRPI0409534A (pt) 2003-04-09 2006-04-18 Genentech Inc métodos para o tratamento de doença autoimune e de artrite reumatóide, método de redução do risco de efeito colateral negativo, usos de um antagonista que se liga a um marcador de superfìcie de células b e uso de um anticorpo que se liga a cd20
CN102512675A (zh) 2004-06-04 2012-06-27 健泰科生物技术公司 用于治疗多发性硬化的方法
EP2548575A1 (en) 2005-02-15 2013-01-23 Duke University Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
WO2006098998A2 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
JP5047947B2 (ja) 2005-05-05 2012-10-10 デューク ユニバーシティ 自己免疫疾患のための抗ｃｄ１９抗体治療
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
MX2009011996A (es) 2007-05-07 2010-04-21 Medimmune Llc Anticuerpos anti-coestimulador inducible y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunologica.
EP3025714B9 (en) 2007-09-14 2020-11-18 Biogen MA Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
KR101361905B1 (ko) 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CA2739663A1 (en) 2008-10-10 2010-05-15 Anaphore, Inc. Polypeptides that bind trail-r1 and trail-r2
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
RU2371201C1 (ru) * 2008-12-15 2009-10-27 Гурий Петрович Ступаков Способ лечения хронических заболеваний
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
MX2012001306A (es) 2009-07-31 2012-02-28 Genentech Inc Inhibicion de matastasis de tumor.
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
WO2011033006A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
KR20130086628A (ko) 2010-11-08 2013-08-02 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
JP6161540B2 (ja) 2011-02-04 2017-07-12 ジェネンテック， インコーポレイテッド Ｆｃ変異体及びそれらの生産方法
MY189494A (en) 2011-03-31 2022-02-16 Genentech Inc Methods of administering beta7 integrin antagonists
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
CA2842481A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CA2863066A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
CN104870056A (zh) 2012-10-05 2015-08-26 弗·哈夫曼-拉罗切有限公司 用于诊断和治疗炎性肠病的方法
KR102182488B1 (ko) 2013-02-25 2020-11-24 제넨테크, 인크. 약물 내성 akt 돌연변이체의 검출 및 치료를 위한 방법 및 조성물
US9682071B2 (en) 2013-03-15 2017-06-20 Intermune, Inc. Methods of improving microvascular integrity
JP6615745B2 (ja) 2013-03-27 2019-12-04 ジェネンテック， インコーポレイテッド ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
JP7054990B2 (ja) 2014-03-27 2022-04-15 ジェネンテック， インコーポレイテッド 炎症性腸疾患の診断及び治療のための方法
WO2015171822A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
WO2016040868A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
MY188799A (en) 2014-12-05 2022-01-04 Genentech Inc Anti-cd79b antibodies and methods of use
HK1244229A1 (zh) 2015-02-26 2018-08-03 F. Hoffmann-La Roche Ag 治疗CROHN病的整联蛋白β7拮抗剂和方法
EP3310378B1 (en) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use
MY193078A (en) 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
JP2018520153A (ja) 2015-06-29 2018-07-26 ジェネンテック， インコーポレイテッド 臓器移植における使用のためのｉｉ型抗ｃｄ２０抗体
RU2753390C1 (ru) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN108431038A (zh) 2015-10-06 2018-08-21 豪夫迈·罗氏有限公司 治疗多发性硬化的方法
SG11201804961UA (en) 2015-12-30 2018-07-30 Genentech Inc Formulations with reduced degradation of polysorbate
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
MX2019006823A (es) 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible.
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
JP2020513280A (ja) 2016-12-14 2020-05-14 プロジェニティ， インコーポレイテッド 消化管疾病の免疫抑制剤による治療
JP7150724B2 (ja) 2016-12-14 2022-10-11 ビオラ・セラピューティクス・インコーポレイテッド 消化管疾病のｔｎｆ阻害薬による治療
WO2018112235A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018112245A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
EP3600414A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
WO2018183934A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
CA3054947A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
CN111601597B (zh) 2017-08-23 2023-10-13 科智生命科学公司 自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3802850B1 (en) 2018-06-01 2025-11-19 BT Bidco, Inc. Devices and systems for gastrointestinal microbiome detection and manipulation
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
US20240252795A1 (en) 2018-11-19 2024-08-01 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20220364171A1 (en) 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CA3106693A1 (en) 2019-02-06 2020-08-13 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
KR20210146986A (ko) 2019-04-02 2021-12-06 상가모 테라퓨틱스, 인코포레이티드 베타-지중해빈혈의 치료 방법
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2023086910A1 (en) 2021-11-12 2023-05-19 Genentech, Inc. Methods of treating crohn's disease using integrin beta7 antagonists
EP4433506A1 (en) 2021-11-16 2024-09-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
EP4633738A1 (en) 2022-12-14 2025-10-22 Pheon Therapeutics Ltd Cytotoxic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2476320B1 (fr) * 1980-02-15 1985-10-25 Guffroy Rene Nouveau reactif immunologique pour la detection en tubes du facteur rhumatoide dans un echantillon biologique et procede de preparation de ce nouveau reactif
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
DE3650184T2 (de) * 1985-12-03 1995-05-11 T Cell Sciences Inc Zellenfreier t-zellenantigenrezeptor und klinische verwendung.
FI891226A7 (fi) * 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon

Also Published As

Publication number Publication date
AU6892994A (en) 1994-10-27
JP3472297B2 (ja) 2003-12-02
NO20002425L (no) 1991-09-20
AU672313B2 (en) 1996-09-26
RU2138512C1 (ru) 1999-09-27
WO1990011294A1 (en) 1990-10-04
DE69006018T3 (de) 2004-01-15
FI914432A0 (fi) 1991-09-20
AU6893094A (en) 1994-11-24
JPH04506512A (ja) 1992-11-12
EP0463101B2 (en) 2003-03-19
AU7650096A (en) 1997-02-13
ES2062519T3 (es) 1994-12-16
DE69006018T2 (de) 1994-05-11
EP0463101B1 (en) 1994-01-12
RO110397B1 (ro) 1996-01-30
AU648753B2 (en) 1994-05-05
DE69006018D1 (de) 1994-02-24
NO913722D0 (no) 1991-09-20
AU5356790A (en) 1990-10-22
NO913722L (no) 1991-09-20
CA2046909A1 (en) 1990-09-22
NO309164B1 (no) 2000-12-18
BG61164B1 (bg) 1997-01-31
FI914432A7 (fi) 1991-09-20
AU6892894A (en) 1994-11-03
KR920700674A (ko) 1992-08-10
ES2062519T5 (es) 2003-07-16
AU6892694A (en) 1994-10-27
EP0463101A1 (en) 1992-01-02
DK0463101T3 (da) 1994-03-14
BG95337A (bg) 1993-12-24

Similar Documents

Publication Publication Date Title
NO20002425D0 (no) FremgangsmÕte for diagnose av, eller forutsigelse av mottagelighet for en T-cellemedient sykdom hos et individ
DE69010785D1 (de) System zum Messen von durch ein Endoskop beobachteten Gegenständen.
DE69018380D1 (de) Verbesserungen für Blutentnahmegeräte.
NO905460D0 (no) Broennsonde.
BR9104431A (pt) Estojo de teste de diagnostico
DK154247C (da) Proevestrimmel til diagnose
FI844676A0 (fi) Diagnostisk test foer a-gruppens streptokocker.
DE68915033D1 (de) Mehrfarbiger Filter für eine Anzeigevorrichtung.
DK412189D0 (da) Sonde og fremgangsmaade til diagnose for muskeldystrofi
GB8630614D0 (en) Analysis testing system
NO901349L (no) Fremgangsmaate for maaling eller testing.
DE69630808D1 (de) Factor v verhältnis bluttest auf empfänglichkeit für thromboembolie
DE69004105D1 (de) Verbrennungsofen für eine zu analysierende Probe.
DE3788054D1 (de) Fühler für zusammengesetzten analysator-tester.
DE58902270D1 (de) Atemanalysesystem.
DE69015714D1 (de) Verbindungs-Prüfsystem.
FI870946A7 (fi) Nopea DNA-testi mikrobien toteamiseksi.
NO882978D0 (no) Innretning for leverfunksjonsproeving.
DK197589D0 (da) Hjaelpemiddel til diagnose
DE3776752D1 (de) Drei-achsen-messfuehler.
DE3874010D1 (de) Diagnostische testvorrichtung.
DE69025440D1 (de) Probensonde
NO882950L (no) Diagnostisk test for stafylokokk-foraarsaket mastitt.
DE69023507D1 (de) Test zur bestimmung der enzymaktivität.
DE3879889D1 (de) Testmeter.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application